"Hela人宮頸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

公司細(xì)胞系形態(tài)漂亮、增殖倍數(shù)高、純度高、功能性強(qiáng)，細(xì)胞培養(yǎng)就跟養(yǎng)孩子一個(gè)樣。養(yǎng)孩子要喂奶，養(yǎng)細(xì)胞要加補(bǔ)液，都需要在前期補(bǔ)充足夠的營(yíng)養(yǎng)，初始狀態(tài)的細(xì)胞或剛剛復(fù)蘇的細(xì)胞還要適量加入血清或細(xì)胞因子來(lái)幫助它們的存活增殖，如果營(yíng)養(yǎng)物質(zhì)缺乏，細(xì)胞就會(huì)不生長(zhǎng)甚至死亡。養(yǎng)孩子要從小培養(yǎng)學(xué)習(xí)，養(yǎng)細(xì)胞也得培養(yǎng)寶寶順利生下來(lái)，你會(huì)經(jīng)常撫摸他，給他看各種顏色，刺激他的五感。細(xì)胞也是一樣，分離后的細(xì)胞需要使用特定的細(xì)胞因子進(jìn)行活化、增殖。另外加入因子的種類(lèi)、因子的濃度、加入時(shí)間、加入順序都會(huì)影響細(xì)胞最終的結(jié)果。養(yǎng)孩子最怕孩子生病，養(yǎng)細(xì)胞最怕被污染，平時(shí)你會(huì)仔細(xì)觀察寶寶是否嘔吐、是否突然哭鬧，猜測(cè)寶寶是否生病了。對(duì)于細(xì)胞，我們也需要時(shí)刻進(jìn)行觀察的，假如培養(yǎng)液渾濁(污染了)，則需要換液后加抗生素；假如細(xì)胞增殖不明顯，形態(tài)變差，則可能是因?yàn)闋I(yíng)養(yǎng)不足了，對(duì)貼壁細(xì)胞可以消化后重新用新的培養(yǎng)基接種并加倍加入細(xì)胞因子含量；對(duì)懸浮細(xì)胞增殖能力不強(qiáng)的，則不著急補(bǔ)液，只是先補(bǔ)加血清、細(xì)胞因子看是否可以好轉(zhuǎn)。培養(yǎng)時(shí)還得全程在無(wú)菌的環(huán)境，一個(gè)小小的偏差，細(xì)胞就會(huì)死亡。

換液周期：每周2-3次

H-719 Cells;背景說(shuō)明：小細(xì)胞肺癌；骨髓轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：半貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Caki2細(xì)胞、H1155細(xì)胞、HuT 102細(xì)胞

BC-3-H-I Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CHP126細(xì)胞、Lewis Lung細(xì)胞、NBL-3細(xì)胞

DU-145 Cells;背景說(shuō)明：DU １４５ 是從一位有３年淋巴細(xì)胞白血病史的前列腺癌患者的腦部轉(zhuǎn)移灶中建立的。該細(xì)胞系未檢測(cè)到激素敏感性，酸性酶陽(yáng)性，單個(gè)的細(xì)胞可在軟瓊脂中形成集落。對(duì)此細(xì)胞和原始腫瘤的亞顯微結(jié)構(gòu)分析可見(jiàn)微絨毛、微絲、細(xì)胞橋粒、線(xiàn)粒體、發(fā)達(dá)的高爾基體和異質(zhì)溶酶體。該細(xì)胞不表達(dá)前列腺抗原。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HRGEC細(xì)胞、Human Pancreatic Duct Epithelial細(xì)胞、Hx-147細(xì)胞

Hela人宮頸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：HeLa是第一個(gè)來(lái)自人體組織經(jīng)連續(xù)培養(yǎng)獲得的非整倍體上皮樣細(xì)胞系，它由GeyGO等在１９５１年從３１歲女性黑人的宮頸癌組織建立。經(jīng)原始組織切片重新觀察，Jones等將其診斷為腺癌。已知該細(xì)胞系含有人乳頭狀瘤病毒HPV１８序列，需在２級(jí)生物安全防護(hù)臺(tái)操作。該細(xì)胞角蛋白陽(yáng)性，p５３表達(dá)量較低，但表達(dá)正常水平的pRB（視網(wǎng)膜母細(xì)胞瘤抑制因子）。

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線(xiàn)：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測(cè)；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺(tái)，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長(zhǎng)特性和后續(xù)的實(shí)驗(yàn)需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長(zhǎng)的比較快，不是著急用的話(huà)，我就會(huì)按1E6個(gè)細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會(huì)適當(dāng)多傳一點(diǎn)；還可通過(guò)顯微鏡計(jì)數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實(shí)驗(yàn)。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

Hela人宮頸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來(lái)源：人源、鼠源等其它物種來(lái)源

COLO 320 DM Cells;背景說(shuō)明：該細(xì)胞可產(chǎn)生５-羥色胺、去甲、、ACTH和甲狀旁腺素。角蛋白、波形蛋白弱陽(yáng)性。培養(yǎng)條件： RPMI １６４０  １０%FBS;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮+貼壁;形態(tài)特性：淋巴細(xì)胞;相關(guān)產(chǎn)品有：HT 1197.T細(xì)胞、WPMY1細(xì)胞、SK-MEL-2-LUC細(xì)胞

C28/I2 Cells;背景說(shuō)明：軟骨；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CHO/dhFr-細(xì)胞、Hos TE-85細(xì)胞、526 mel細(xì)胞

HLEB-3 Cells;背景說(shuō)明：晶狀體；Ad１２-SV４０轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MM1細(xì)胞、Ramos-2G6-4C10細(xì)胞、U266B1細(xì)胞

CCRF/CEM/0 Cells;背景說(shuō)明：G.E. Foley 等人建立了類(lèi)淋巴母細(xì)胞細(xì)胞株CCRF-CEM。 細(xì)胞是１９６４年１１月從一位四歲白人女性急性淋巴細(xì)胞白血病患者的外周血白血球衣中得到。此細(xì)胞系從香港收集而來(lái)。;傳代方法：１：２傳代。３天內(nèi)可長(zhǎng)滿(mǎn)。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：H9c2(2-1)細(xì)胞、HCC-1419細(xì)胞、H661細(xì)胞

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線(xiàn)：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞復(fù)蘇后貼壁細(xì)胞較少的問(wèn)題分析：總結(jié)１：復(fù)蘇過(guò)程沒(méi)有問(wèn)題，是否是從拿出直接放入溫水，還有培養(yǎng)箱，二氧化碳濃度，培養(yǎng)基、PH值等環(huán)節(jié)。要么加GAO濃度FBS １５-２０%，看看能否幫助貼壁，當(dāng)然也需要考慮血清問(wèn)題，還有確信拿來(lái)的細(xì)胞沒(méi)問(wèn)題?？偨Y(jié)２：首先應(yīng)該懷疑凍存，實(shí)際上復(fù)蘇出問(wèn)題的可能非常小，因?yàn)椴僮骱?jiǎn)單，而且死板。１、你凍存的時(shí)候是不是消化的時(shí)間過(guò)長(zhǎng)，這是一般人所注意不到的，即使書(shū)上也不講這個(gè)問(wèn)題，太長(zhǎng)的消化時(shí)間會(huì)讓細(xì)胞復(fù)蘇時(shí)失去貼壁能力，表現(xiàn)為先貼后死，原因是在你復(fù)蘇的時(shí)候細(xì)胞已進(jìn)入凋亡程序，不可逆轉(zhuǎn)的死亡。２、你的凍存HAO不HAO，是什么，甘油還是DMSO，質(zhì)量非常重要，否則也會(huì)死亡。３、你的凍存的量加的是不是太多，AC推薦是不超過(guò)７%，大于５%，太多也不HAO。４、你在凍存的時(shí)候是不是把DMSO混均勻，這個(gè)有一些影響，但不算太大。５、你的凍存是否按部就班，就是所溫度梯度是不是把握嚴(yán)格，很多人容易忘卻這個(gè)事情，因?yàn)檫@個(gè)東西流程長(zhǎng)。６、如果你細(xì)胞污染，你是否能很快看到，我比我的導(dǎo)師能早一天看到污染。從這個(gè)角度講建議去除離心這步。７、你的細(xì)胞在凍存前是否過(guò)密。還有，不贊成孵箱污染這個(gè)概念的，所有在一個(gè)孵箱里的細(xì)胞都污染一個(gè)細(xì)菌的話(huà)，這個(gè)細(xì)菌是源于孵箱的，但這不代表孵箱污染，因?yàn)榉跸錈o(wú)論你如何處理都有大量的細(xì)菌，問(wèn)題在操作。每次污染的原因都要盡可能的找，以后就不犯同樣的問(wèn)題，這個(gè)很重要，不能靠猜，否則你就有可能細(xì)胞養(yǎng)絕Zui后換課題，這個(gè)見(jiàn)得太多了，別不當(dāng)會(huì)事。

WEHI3 Cells;背景說(shuō)明：白血病；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs294T細(xì)胞、RPMI-7951細(xì)胞、SGC7901/DDP細(xì)胞

Colo16 Cells;背景說(shuō)明：皮膚鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HBMEC細(xì)胞、NCIH520細(xì)胞、Wills Eye Research Institute-Retinoblastoma-1細(xì)胞

SU8686 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BRL3A細(xì)胞、PANC-28細(xì)胞、LuCL4細(xì)胞

Tu-212 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SNU-475細(xì)胞、NCI-H526細(xì)胞、V79-4細(xì)胞

MDA MB 361 Cells;背景說(shuō)明：該細(xì)胞源自４０歲女性乳腺癌的腦轉(zhuǎn)移組織。;傳代方法： １：２—１：６傳代，每周換液２—３次;生長(zhǎng)特性：松散貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H3255_DA細(xì)胞、Renal Proximal Tubule Epithelial Cells/TERT-immortalized 1細(xì)胞、HFF-1細(xì)胞

H-1688 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA330細(xì)胞、LLC-PK-1細(xì)胞、Moorfields/Institute of Ophthalmology-Muller 1細(xì)胞

Vero 76 clone E6 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：EFO 27細(xì)胞、HMCB細(xì)胞、PaTu-8988s細(xì)胞

B104 [Rat neuroblastoma] Cells;背景說(shuō)明：神經(jīng)母細(xì)胞瘤；BDIX;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：C57/B6-L細(xì)胞、HHL5細(xì)胞、C166細(xì)胞

GM02132C Cells;背景說(shuō)明：來(lái)源于一位６１歲的男性漿細(xì)胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測(cè)到重鏈。;傳代方法：按１：２傳代，５-６小時(shí)可以看到細(xì)胞分裂;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HR-8348細(xì)胞、GLC82細(xì)胞、MC57G細(xì)胞

LC1/Sq Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs 822.T細(xì)胞、Be-Wo細(xì)胞、HCC-1806細(xì)胞

aTC1 Clone 6 Cells;背景說(shuō)明：胰島素瘤；a細(xì)胞；C５７BL/６xDBA/２;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：D407 RPE細(xì)胞、NCTC 1469細(xì)胞、4T1細(xì)胞

CZ-1 Cells;背景說(shuō)明：骨髓瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：ST細(xì)胞、EFO-27細(xì)胞、HMC細(xì)胞

GM03320 Cells;背景說(shuō)明：該細(xì)胞是１９６７年４月由NicholsWW,LeeJ和DwightS建立，來(lái)源于一名１３月齡白人男嬰腹部腫塊，臨床診斷為神經(jīng)母細(xì)胞瘤，伴有極少部位的類(lèi)器官樣分化。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：存在兩種細(xì)胞類(lèi)型，小的神經(jīng)母細(xì)胞樣細(xì)胞和大的透明成纖維樣細(xì)胞;相關(guān)產(chǎn)品有：SK.OV.3細(xì)胞、675T細(xì)胞、L-02細(xì)胞

NCI N87 Cells;背景說(shuō)明：NCI-N８７細(xì)胞表達(dá)表面糖蛋白癌胚抗原(CEA)和TAG７２,并且沒(méi)有左旋多巴胺脫羧酶(DDC)活性。它們的血管活性的腸肽(VIP)受體活性極低并缺乏胃泌激素受體。它們表達(dá)蕈毒堿膽堿受體。沒(méi)有證據(jù)表明存在N-myc,L-myc,myb和EGF受體基因的重組。這個(gè)細(xì)胞株表達(dá)的c-myc和c-erb-B２RNA水平與其它細(xì)胞株相當(dāng)。以下基因不表達(dá):N-myc,L-myc,c-cis,IGF-２,或胃泌激素釋放肽。報(bào)道NCI-N８７細(xì)胞的植板率為４.３%。;傳代方法：消化１５-２０分鐘。１：２。４-５天長(zhǎng)滿(mǎn)。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MGC-803細(xì)胞、MV4-11細(xì)胞、NCIH208細(xì)胞

H-1238 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：ARH77細(xì)胞、Anip[973]細(xì)胞、THLE-3細(xì)胞

Rat Fetal Lung-6 Cells;背景說(shuō)明：胚肺；成纖維細(xì)胞；SD大鼠;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：JB6 [Mouse]細(xì)胞、HUV-EC-C細(xì)胞、SK-MEL-2細(xì)胞

SkChA1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：REC1細(xì)胞、H-146細(xì)胞、LU165細(xì)胞

143B pML BK TK Cells(提供STR鑒定圖譜)

Abcam HeLa FXR1 KO Cells(提供STR鑒定圖譜)

AG21276 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRF229 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XG446 Cells(提供STR鑒定圖譜)

C0189 Cells(提供STR鑒定圖譜)

CW60066 Cells(提供STR鑒定圖譜)

DTE 1-6-4 Cells(提供STR鑒定圖譜)

GM04208 Cells(提供STR鑒定圖譜)

NCI-H165 Cells;背景說(shuō)明：非小細(xì)胞肺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H69C細(xì)胞、MC-4細(xì)胞、HPF細(xì)胞

Hela人宮頸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

RPMI No. 1846 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H2081細(xì)胞、MDA-MB-231 #4175細(xì)胞、SK-OV-3細(xì)胞

A9(Hamprecht) Cells;背景說(shuō)明：皮下結(jié)締組織；自發(fā)永生；雄性；C３H/An;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SCC-15細(xì)胞、HCC-1359細(xì)胞、PC-14細(xì)胞

Panc 08.13 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：AZ 521細(xì)胞、HKF細(xì)胞、HSAS1細(xì)胞

Wien 133 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H1404細(xì)胞、KLM-1細(xì)胞、MNNG細(xì)胞

NT2D1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：GAK細(xì)胞、NL20SV細(xì)胞、D10細(xì)胞

7265PDA Cells(提供STR鑒定圖譜)

HIT.T15 Cells;背景說(shuō)明：胰島β細(xì)胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：M3 Clone M-3細(xì)胞、H7721細(xì)胞、Capan 1細(xì)胞

CX-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MIA-Pa-Ca-2細(xì)胞、BV-2細(xì)胞、GM03320細(xì)胞

SW954 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：KNS81細(xì)胞、MIA-Pa-Ca-2細(xì)胞、HCC15細(xì)胞

PLC/PRF5 Cells;背景說(shuō)明：該細(xì)胞系分泌乙肝病毒表面抗原（HBsAg）。 此細(xì)胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KYSE 510細(xì)胞、SUPB15細(xì)胞、LC1sq細(xì)胞

KRC Y Cells;背景說(shuō)明：腎透明細(xì)胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：L540細(xì)胞、B-95-8細(xì)胞、McG-1細(xì)胞

Hs-27 Cells;背景說(shuō)明：包皮；成纖維細(xì)胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SKNBE2細(xì)胞、NTERA2-D1細(xì)胞、SNU5細(xì)胞

OVCA 420 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：IOSE 80細(xì)胞、RT-112細(xì)胞、NK92MI細(xì)胞

SUDHL-2 Cells;背景說(shuō)明：彌漫性大細(xì)胞淋巴瘤；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LP-1細(xì)胞、SK-N-BE-2細(xì)胞、8226細(xì)胞

GM21889 Cells(提供STR鑒定圖譜)

HAP1 MARK3 (-) 1 Cells(提供STR鑒定圖譜)

TE-32 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，３-４天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：梭型和大的多核細(xì)胞;相關(guān)產(chǎn)品有：P3-Jiyoye細(xì)胞、hTERT-RPE細(xì)胞、EVSAT細(xì)胞

PG [Human lung carcinoma] Cells;背景說(shuō)明：巨細(xì)胞肺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH2009細(xì)胞、LWnt3A細(xì)胞、CL11細(xì)胞

UMRC2 Cells;背景說(shuō)明：腎透明細(xì)胞癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：32D/cl3細(xì)胞、Malme3M細(xì)胞、HBZY-1細(xì)胞

HCC2108 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BNCL2細(xì)胞、MXI細(xì)胞、SW1783細(xì)胞

HM1900 Cells;背景說(shuō)明：小膠質(zhì) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs 636.T細(xì)胞、RFL6細(xì)胞、Immortal Pig Intestinal-2I細(xì)胞

8226/S Cells;背景說(shuō)明：來(lái)源于一位６１歲的男性漿細(xì)胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測(cè)到重鏈。;傳代方法：按１：２傳代，５-６小時(shí)可以看到細(xì)胞分裂;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：LCD細(xì)胞、HCC-4006細(xì)胞、293細(xì)胞

HIT T-15 Cells;背景說(shuō)明：胰島β細(xì)胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CORL23細(xì)胞、SGC 7901細(xì)胞、SK RC 20細(xì)胞

YH-13 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HEp-2細(xì)胞、NT2細(xì)胞、SHEE細(xì)胞

HPSI0616i-beyk_6 Cells(提供STR鑒定圖譜)

KAUSTi007-A Cells(提供STR鑒定圖譜)

MEO clone 515 Cells(提供STR鑒定圖譜)

NHEM680 Cells(提供STR鑒定圖譜)

Raji CD19 Low Cells(提供STR鑒定圖譜)

U-87MG ATCC ECE1 KO Cells(提供STR鑒定圖譜)

UM29-3 PGD Cells(提供STR鑒定圖譜)

HG01367 Cells(提供STR鑒定圖譜)

HCC1143 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Biopsy xenograft of Pancreatic Carcinoma line-3細(xì)胞、NL-20細(xì)胞、MDCK-II細(xì)胞

RPMI1788 Cells;背景說(shuō)明：B淋巴細(xì)胞；EBV轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H1436細(xì)胞、UM-UC14細(xì)胞、NCI-H1436細(xì)胞

HC11 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MM6細(xì)胞、HEC-251細(xì)胞、NUGC4細(xì)胞

K299 Cells;背景說(shuō)明：間變性大細(xì)胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CL34細(xì)胞、H-2347細(xì)胞、NK-92細(xì)胞

U14 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：IFRS1細(xì)胞、DR2R 1610細(xì)胞、H-1838細(xì)胞

U14 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：IFRS1細(xì)胞、DR2R 1610細(xì)胞、H-1838細(xì)胞

Chang Cells Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Z138細(xì)胞、G-361細(xì)胞、KYSE450細(xì)胞

130 T Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，３-４天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：梭型和大的多核細(xì)胞;相關(guān)產(chǎn)品有：H2106細(xì)胞、3396細(xì)胞、MDAMB231細(xì)胞

Th17 Cells;背景說(shuō)明：輔助性T Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MIN-6細(xì)胞、SHIN3細(xì)胞、Eph4 1424細(xì)胞

PL-12 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MOLT-3細(xì)胞、NCIH747細(xì)胞、NIE-115細(xì)胞

U251-MG Cells;背景說(shuō)明：U-２５１ MG分離至一位患者的膠質(zhì)母細(xì)胞瘤組織。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：Leukemia L1210細(xì)胞、DMS-153細(xì)胞、CCD33Co細(xì)胞

U-251 MG Cells;背景說(shuō)明：U-２５１ MG分離至一位患者的膠質(zhì)母細(xì)胞瘤組織。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：AML-EOL-1細(xì)胞、AMO1細(xì)胞、PC615.3細(xì)胞

UWB1.289 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：118MG細(xì)胞、NCIH196細(xì)胞、FD-LSC-1細(xì)胞

KHYG-1 Cells;背景說(shuō)明：NK細(xì)胞淋巴瘤/白血病；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Y3細(xì)胞、GM00346細(xì)胞、BALB 3T3 clone A31細(xì)胞

HBVP Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH1793細(xì)胞、Panc-8_13細(xì)胞、Reuber H35細(xì)胞

ST90/MGH12 Cells(提供STR鑒定圖譜)

FAK+/+ Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８?jìng)鞔?;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NCI-H1869細(xì)胞、Melanoma 14細(xì)胞、RD-ES細(xì)胞

NCIH322 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SW-1116細(xì)胞、H-865細(xì)胞、Henrietta Lacks cells細(xì)胞

J111 Cells;背景說(shuō)明：?jiǎn)魏思?xì)胞白血病;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH650細(xì)胞、Hs819T細(xì)胞、University of Michigan-Urothelial Carcinoma-14細(xì)胞

B16-F10 Cells;背景說(shuō)明：B１６-F１０是B１６-F０的亞系。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿(mǎn)。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Sp2/mIL-6細(xì)胞、HEK293-A細(xì)胞、EU-4細(xì)胞

B16 subline B78 Cells;背景說(shuō)明：該細(xì)胞源于C５７BL/６J小鼠黑色素瘤，可以產(chǎn)生黑色素，同基因小鼠體內(nèi)移植可成瘤;傳代方法：１：３傳代，２-３天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：梭形;相關(guān)產(chǎn)品有：SKMEL-2細(xì)胞、DMS-273細(xì)胞、CALU1細(xì)胞

BC-028 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：FHC細(xì)胞、H446細(xì)胞、IAR20細(xì)胞

Hela人宮頸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

CAL 12 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PTK2細(xì)胞、HO8910/PM細(xì)胞、IPLB-SF 21細(xì)胞

HeLaS3 Cells;背景說(shuō)明：該細(xì)胞是１９５５年由PuckTT,MarcusPI和CieciuraSJ建系的，含HPV-１８序列；角蛋白陽(yáng)性；可用于與染色體突變、細(xì)胞營(yíng)養(yǎng)、集落形成相關(guān)的哺乳動(dòng)物細(xì)胞的克隆分析。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KP-N-RT-BM細(xì)胞、HCC0202細(xì)胞、AC29細(xì)胞

BT 549 Cells;背景說(shuō)明：該細(xì)胞１９７８年由W.G.Coutinho和E.Y.Lasfargues建系，源自一位７２歲患有乳腺導(dǎo)管癌的白人女性，來(lái)源組織包括乳頭及浸潤(rùn)導(dǎo)管。該細(xì)胞形態(tài)包括上皮樣細(xì)胞及多核巨細(xì)胞，可分泌一種粘性物質(zhì)。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：DU4475細(xì)胞、HS-729細(xì)胞、Mouse podocyte細(xì)胞

KE-39 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs706T細(xì)胞、LAD-2細(xì)胞、Wills Eye Research Institute-Retinoblastoma-1細(xì)胞

H1666_DA Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng)，松散;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：RK13細(xì)胞、RT-BM 1細(xì)胞、ECC 12細(xì)胞

WEHI164 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RMS 13細(xì)胞、MDA-MB436細(xì)胞、BC-3-H-I細(xì)胞

HuT 78 Cells;背景說(shuō)明：皮膚；T淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RPMI no 8226細(xì)胞、EHEB細(xì)胞、HR-8348細(xì)胞

PCI-4B Cells;背景說(shuō)明：喉鱗癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：KYSE-410細(xì)胞、Rca-B細(xì)胞、NCIH1755細(xì)胞

BayGenomics ES cell line RRR019 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHC444 Cells(提供STR鑒定圖譜)

HIL12R1.2B10 Cells(提供STR鑒定圖譜)

PCRP-ELF3-8F6 Cells(提供STR鑒定圖譜)

COS1NR Cells(提供STR鑒定圖譜)

HPS1330 Cells(提供STR鑒定圖譜)

" "PubMed=13261081

Moore A.E., Sabachewsky L., Toolan H.W.

Culture characteristics of four permanent lines of human cancer cells.

Cancer Res. 15:598-602(1955)

PubMed=16589695; DOI=10.1073/pnas.41.7.432; PMCID=PMC528114

Puck T.T., Marcus P.I.

A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: the use of X-irradiated cells to supply conditioning factors.

Proc. Natl. Acad. Sci. U.S.A. 41:432-437(1955)

PubMed=14031339

Katzberg A.A.

The effect of space flights on living human cells aboard Discoverer XVIII.

Tech. Doc. Rep. SAMTDR USAF Sch. Aerosp. Med. 62:43.1-43.4(1962)

PubMed=14185313; DOI=10.1126/science.146.3641.241

Cell Culture Collection Committee

Animal cell strains. The Cell Culture Collection Committee has assembled and certified 23 strains of animal cells.

Science 146:241-243(1964)

PubMed=5668122; DOI=10.3181/00379727-128-33119

Peterson W.D. Jr., Stulberg C.S., Swanborg N.K., Robinson A.R.

Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures determined by sucrose-agar gel and cellulose acetate zymograms.

Proc. Soc. Exp. Biol. Med. 128:772-776(1968)

DOI=10.1007/BF02618370

Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.

The animal cell culture collection.

In Vitro 5:1-16(1970)

PubMed=4942173; DOI=10.1097/00006250-197112000-00028

Jones H.W. Jr., McKusick V.A., Harper P.S., Wuu K.-D.

George Otto Gey (1899-1970). The HeLa cell and a reappraisal of its origin.

Obstet. Gynecol. 38:945-949(1971)

DOI=10.1007/978-1-4757-1647-4_13

Biedler J.L.

Chromosome abnormalities in human tumor cells in culture.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York; USA (1975)

PubMed=1246620; DOI=10.1126/science.1246620

Hsu S.H., Schacter B.Z., Delaney N.L., Miller T.B., McKusick V.A., Kennett R.H., Bodmer J.G., Young D., Bodmer W.F.

Genetic characteristics of the HeLa cell.

Science 191:392-394(1976)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6358339; DOI=10.1093/jhmas/38.4.415

Brown R.W., Henderson J.H.M.

The mass production and distribution of HeLa cells at Tuskegee Institute, 1953-55.

J. Hist. Med. Allied Sci. 38:415-431(1983)

PubMed=6401685; DOI=10.1007/BF02617989

Halton D.M., Peterson W.D. Jr., Hukku B.

Cell culture quality control by rapid isoenzymatic characterization.

In Vitro 19:16-24(1983)

PubMed=6825208; DOI=10.1093/carcin/4.2.199

Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd

Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.

Carcinogenesis 4:199-205(1983)

PubMed=2983228; DOI=10.1038/314111a0

Schwarz E., Freese U.-K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H.

Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.

Nature 314:111-114(1985)

PubMed=2990217; PMCID=PMC1888002

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Am. J. Pathol. 119:361-366(1985)

CLPUB00262

Gold M.

A conspiracy of cells. One woman's immortal legacy and the medical scandal it caused.

(In book) ISBN 9780887060991; pp.1-171; State University of New York Press; Albany; USA (1986)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3028716; DOI=10.1159/000132342

Popescu N.C., DiPaolo J.A., Amsbaugh S.C.

Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes.

Cytogenet. Cell Genet. 44:58-62(1987)

PubMed=3180844; DOI=10.1159/000132579

Chen T.-R.

Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes.

Cytogenet. Cell Genet. 48:19-24(1988)

PubMed=3371749; DOI=10.1016/0090-8258(88)90029-7

Grenman S.E., Shapira A., Carey T.E.

In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen.

Gynecol. Oncol. 30:228-238(1988)

PubMed=1522048; DOI=10.1007/BF02634140

Kataoka E., Honma M., Ohnishi K., Sofuni T., Mizusawa H.

Application of highly polymorphic DNA markers to the identification of HeLa cell sublines.

In Vitro Cell. Dev. Biol. Anim. 28:553-556(1992)

PubMed=8380785; DOI=10.1006/gyno.1993.1016

Iwasaka T., Oh-uchida M., Matsuo N., Yokoyama M., Fukuda K., Hara K., Fukuyama K., Hori K., Sugimori H.

Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines.

Gynecol. Oncol. 48:104-109(1993)

PubMed=9892199

Macville M.V.E., Schrock E., Padilla-Nash H.M., Keck C., Ghadimi B.M., Zimonjic D.B., Popescu N.C., Ried T.

Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping.

Cancer Res. 59:141-150(1999)

PubMed=10423141; DOI=10.1099/0022-1317-80-7-1725

Meissner J.D.

Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines.

J. Gen. Virol. 80:1725-1733(1999)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12001993; DOI=10.1038/nrc775

Masters J.R.W.

HeLa cells 50 years on: the good, the bad and the ugly.

Nat. Rev. Cancer 2:315-319(2002)

PubMed=12793746; DOI=10.1269/jrr.43.s133

Ohnishi T., Ohnishi K., Takahashi A., Taniguchi Y., Sato M., Nakano T., Nagaoka S.

Detection of DNA damage induced by space radiation in Mir and space shuttle.

J. Radiat. Res. 43 Suppl. 1:S133-S136(2002)

PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)

PubMed=15302935; DOI=10.1073/pnas.0404720101; PMCID=PMC514446

Beausoleil S.A., Jedrychowski M.P., Schwartz D., Elias J.E., Villen J., Li J.-X., Cohn M.A., Cantley L.C., Gygi S.P.

Large-scale characterization of HeLa cell nuclear phosphoproteins.

Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004)

PubMed=15531914; DOI=10.1038/sj.onc.1208235

Baldus S.E., Schwarz E., Lohrey C., Zapatka M., Landsberg S., Hahn S.A., Schmidt D., Dienes H.-P., Schmiegel W.H., Schwarte-Waldhoff I.

Smad4 deficiency in cervical carcinoma cells.

Oncogene 24:810-819(2005)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

PubMed=17311676; DOI=10.1186/1471-2164-8-53; PMCID=PMC1805756

Kloth J.N., Oosting J., van Wezel T., Szuhai K., Knijnenburg J., Gorter A., Kenter G.G., Fleuren G.J., Jordanova E.S.

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

BMC Genomics 8:53.1-53.13(2007)

PubMed=19450234; DOI=10.2144/000113089; PMCID=PMC2696096

Rahbari R., Sheahan T., Modes V., Collier P., Macfarlane C.M., Badge R.M.

A novel L1 retrotransposon marker for HeLa cell line identification.

BioTechniques 46:277-284(2009)

PubMed=19722756; DOI=10.5858/133.9.1463

Lucey B.P., Nelson-Rees W.A., Hutchins G.M.

Henrietta Lacks, HeLa cells, and cell culture contamination.

Arch. Pathol. Lab. Med. 133:1463-1467(2009)

CLPUB00377

Skloot R.L.

The immortal life of Henrietta Lacks.

(In book) ISBN 9781400052172; pp.1-400; Random House; New York; USA (2010)

CLPUB00468

Javitt G.H.

Why not take all of me? Reflections on the immortal life of Henrietta Lacks and the status of participants in research using human specimens.

Minn. J. Law Sci. Technol. 11:713-755(2010)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

J. Virol. Methods 164:116-121(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17; PMCID=PMC3039570

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=22068331; DOI=10.1038/msb.2011.81; PMCID=PMC3261714

Nagaraj N., Wisniewski J.R., Geiger T., Cox J., Kircher M., Kelso J., Paabo S., Mann M.

Deep proteome and transcriptome mapping of a human cancer cell line.

Mol. Syst. Biol. 7:548-548(2011)

PubMed=21937730; DOI=10.1074/mcp.M111.011429; PMCID=PMC3316722

Boisvert F.-M., Ahmad Y., Gierlinski M., Charriere F., Lamont D., Scott M., Barton G., Lamond A.I.

A quantitative spatial proteomics analysis of proteome turnover in human cells.

Mol. Cell. Proteomics 11:M111.011429-M111.011429(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22412903; DOI=10.1371/journal.pone.0032667; PMCID=PMC3296745

Vazquez-Mena O., Medina-Martinez I., Juarez-Torres E., Barron V., Espinosa A., Villegas-Sepulveda N., Gomez-Laguna L., Nieto-Martinez K., Orozco L., Roman-Bassaure E., Munoz Cortez S., Borges Ibanez M., Venegas-Vega C.A., Guardado-Estrada M., Rangel-Lopez A., Kofman S., Berumen J.

Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.

PLoS ONE 7:E32667-E32667(2012)

CLPUB00507

Pultarova T.

HeLa cells: immortal space travellers.

Space Saf. Mag. 7:10-12(2013)

PubMed=23205564; DOI=10.1021/pr300859k

Malerod H., Graham R.L.J., Sweredoski M.J., Hess S.

Comprehensive profiling of N-linked glycosylation sites in HeLa cells using hydrazide enrichment.

J. Proteome Res. 12:248-259(2013)

PubMed=23336012; DOI=10.1371/journal.pone.0054672; PMCID=PMC3545996

Horvat T., Dezeljin M., Redzic I., Barisic D., Herak Bosnar M., Lauc G., Zoldos V.

Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors.

PLoS ONE 8:E54672-E54672(2013)

PubMed=23925224; DOI=10.1038/500141a; PMCID=PMC5101952

Hudson K.L., Collins F.S.

Biospecimen policy: family matters.

Nature 500:141-142(2013)

PubMed=23925245; DOI=10.1038/nature12064; PMCID=PMC3740412

Adey A.C., Burton J.N., Kitzman J.O., Hiatt J.B., Lewis A.P., Martin B.K., Qiu R.-L., Lee C., Shendure J.

The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.

Nature 500:207-211(2013)

PubMed=24134916; DOI=10.1186/1755-8166-6-44; PMCID=PMC3879223

McCormack A., Fan J.-L., Duesberg M., Bloomfield M., Fiala C., Duesberg P.H.

Individual karyotypes at the origins of cervical carcinomas.

Mol. Cytogenet. 6:44.1-44.23(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=24696503; DOI=10.1074/mcp.M113.035170; PMCID=PMC4047476

Guo X.-F., Trudgian D.C., Lemoff A., Yadavalli S., Mirzaei H.

Confetti: a multiprotease map of the HeLa proteome for comprehensive proteomics.

Mol. Cell. Proteomics 13:1573-1584(2014)

PubMed=24908793

Gilgenkrantz S.

Sixty years of HeLa cell cultures.

Hist. Sci. Med. 48:139-144(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

CLPUB00376

Verspaget C.J.

Unruly bodies: monstrous readings of biotechnology.

Thesis PhD (2015); Curtin University; Perth; Australia

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25807930; DOI=10.1002/anie.201500342; PMCID=PMC4471546

Broncel M., Serwa R.A., Ciepla P., Krause E., Dallman M.J., Magee A.I., Tate E.W.

Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.

Angew. Chem. Int. Ed. Engl. 54:5948-5951(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639

Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Anal. Chem. 87:12016-12023(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28078501; DOI=10.1007/s11626-016-0128-8

Ambrose C.T.

The Tissue Culture Laboratory of Dr. George Otto Gey 60 yrs ago as recalled by a former student.

In Vitro Cell. Dev. Biol. Anim. 53:467-473(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28261610; DOI=10.1155/2017/4180703; PMCID=PMC5316418

Kontostathi G., Zoidakis J., Makridakis M., Lygirou V., Mermelekas G., Papadopoulos T., Vougas K., Vlamis-Gardikas A., Drakakis P., Loutradis D., Vlahou A., Anagnou N.P., Pappa K.I.

Cervical cancer cell line secretome highlights the roles of transforming growth factor-beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on cervical carcinogenesis.

BioMed Res. Int. 2017:4180703.1-4180703.15(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009; PMCID=PMC5493283

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174; PMCID=PMC5689691

Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Oncotarget 8:86369-86383(2017)

PubMed=30175587; DOI=10.1021/acs.jproteome.8b00392

Robin T., Bairoch A., Muller M., Lisacek F., Lane L.

Large-scale reanalysis of publicly available HeLa cell proteomics data in the context of the Human Proteome Project.

J. Proteome Res. 17:4160-4170(2018)

PubMed=30778230; DOI=10.1038/s41587-019-0037-y

Liu Y.-S., Mi Y., Mueller T., Kreibich S., Williams E.G., Van Drogen A., Borel C., Frank M., Germain P.-L., Bludau I., Mehnert M., Seifert M., Emmenlauer M., Sorg I., Bezrukov F., Sloan-Bena F., Zhou H., Dehio C., Testa G., Saez-Rodriguez J., Antonarakis S.E., Hardt W.-D., Aebersold R.

Multi-omic measurements of heterogeneity in HeLa cells across laboratories.

Nat. Biotechnol. 37:314-322(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687

Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.

Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.

Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31433507; DOI=10.15252/embj.2018100847; PMCID=PMC6826212

Hardman G., Perkins S., Brownridge P.J., Clarke C.J., Byrne D.P., Campbell A.E., Kalyuzhnyy A., Myall A., Eyers P.A., Jones A.R., Eyers C.E.

Strong anion exchange-mediated phosphoproteomics reveals extensive human non-canonical phosphorylation.

EMBO J. 38:e100847.1-e100847.22(2019)

PubMed=31790455; DOI=10.1371/journal.pone.0225466; PMCID=PMC6886862

Hu W.-E., Zhang X., Guo Q.-F., Yang J.-W., Yang Y., Wei S.-C., Su X.-D.

HeLa-CCL2 cell heterogeneity studied by single-cell DNA and RNA sequencing.

PLoS ONE 14:E0225466-E0225466(2019)

PubMed=33389257; DOI=10.1007/s10096-020-04106-0; PMCID=PMC7778494

Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.

Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.

Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)"